Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 134
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01524991 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | ||
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | ||
| NCT00216060 | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy | ||
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | ||
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | ||
| NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | ||
| NCT02549209 | Pembro/Carbo/Taxol in Endometrial Cancer | ||
| NCT05583708 | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | ||
| NCT00216138 | Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck | ||
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | ||
| NCT06392841 | Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations | ||
| NCT00572572 | Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors | ||
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | ||
| NCT03448718 | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | ||
| NCT02365766 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | ||
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | ||
| NCT00632541 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | ||
| NCT03272217 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | ||
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | ||
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | ||
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | ||
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | ||
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | ||
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | ||
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | ||
| NCT03871153 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer | ||
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | ||
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | ||
| NCT00773474 | Lonafarnib in Metastatic Breast Cancer | ||
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | ||
| NCT01232881 | Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer | ||
| NCT00859339 | Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | ||
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | ||
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | ||
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | ||
| NCT04364048 | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | ||
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | ||
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | ||
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | ||
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | ||
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | ||
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | ||
| NCT04848337 | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | ||
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | ||
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | ||
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | ||
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | ||
| NCT00216216 | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer | ||
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma |
